Overview of Dr. Samuel
Dr. Michael Samuel is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and New York-Presbyterian Hospital. He received his medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 8 years. He is one of 378 doctors at New York-Presbyterian Hospital and one of 378 doctors at New York-Presbyterian Hospital who specialize in Oncology. He has more than 10 publications and over 500 citings.
Office
520 E 70th St
# Starr
New York, NY 10021Fax+1 646-962-0115
Education & Training
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2012 - 2015
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2009 - 2012
- State University of New York Downstate Medical Center College of MedicineClass of 2009
Certifications & Licensure
- NY State Medical License 2015 - 2026
Publications & Presentations
PubMed
- 378 citationsSomatic mutations precede acute myeloid leukemia years before diagnosis.Pinkal Desai, Nuria Mencia-Trinchant, Oleksandr Savenkov, Michael S. Simon, Gloria Cheang
Nature Medicine. 2018-07-01 - 107 citationsProgressive ataxia and palatal tremor (PAPT) Clinical and MRI assessment with review of palatal tremorsMichael Samuel, Nurhan Torun, Paul J. Tuite, James A. Sharpe, Anthony E. Lang
Brain. 2004-06-01 - 2 citationsPhase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy.Sangmin Lee, Pinkal Desai, Bianca Edirisinghe, Samantha Pianello, Tania J. Curcio
Leukemia & Lymphoma. 2021-01-28
Abstracts/Posters
- Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative NeoplasmsMichael B. Samuel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- CPX-351 As First Intensive Therapy for Elderly Patients with AMLMichael B. Samuel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive ChemotherapyMichael B. Samuel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: